amantadine and 2019 Novel Coronavirus Disease studies

amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source

Research Excerpts

Excerpt	Relevance	Reference
"Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection."	5.56	Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020)
"Amantadine has been proposed as a treatment for COVID-19 because it shows anti-SARS-CoV-2 activity in vitro."	3.30	Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study. ( Barczyk, A; Barczyk, M; Boda, Ł; Cofta, S; Czajkowska-Malinowska, M; Duława, J; Dyrbuś, M; Farnik, M; Harat, R; Huk, M; Kotecka, S; Kuna, P; Nahorecki, A; Nasiłowski, J; Naumnik, W; Przybylski, G; Skoczyński, S; Słaboń-Willand, M; Wita, K; Zioło, G, 2023)
"To compare the groups of Parkinson's Disease (PD) patients who were administered amantadine chronically and those who did not take this medication in the context of the incidence and severity of COVID-19 infection."	1.91	Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study. ( Dulski, J; Kasprzak, J; Koziorowski, D; Kwaśniak-Butowska, M; Przytuła, F; Roszmann, A; Schinwelski, M; Śmiłowska, K; Sołtan, W; Sławek, J, 2023)
"Amantadine has complex activity including antiviral, antiinflammatory and dopaminergic effects."	1.72	The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design. ( Bonek, R; Chełstowski, W; Dąbrowski, P; Dec, M; Fiedor, P; Gala-Błądzińska, A; Goch, A; Grieb, P; Kiciak, S; Król, ZJ; Papuć, E; Rejdak, K; Segiet, A; Zasybska, A; Łukasiak, J, 2022)
"Amantadine was approved as an antiviral drug against influenza A, and antiviral activity against SARS-CoV-2 has been reasoned by analogy but without data."	1.62	Amantadine Inhibits SARS-CoV-2 In Vitro. ( Danysz, W; Eisele, KH; Fink, K; Grossegesse, M; Neumann, M; Nitsche, A, 2021)
"Amantadine was approved by the US Food and Drug Administration in 1968 as a prophylactic agent for influenza and later for Parkinson's disease."	1.56	Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment. ( Polymeropoulos, MH; Przychodzen, BP; Smieszek, SP, 2020)
"Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection."	1.56	Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	22 (100.00)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms in Patients Infected With the SARS-CoV-2 Virus[NCT04854759]	Phase 3	200 participants (Anticipated)	Interventional	2021-03-15	Recruiting
Amantadine for COVID-19: A Randomized, Placebo Controlled, Double-blinded, Clinical Trial[NCT04894617]	Phase 3	226 participants (Anticipated)	Interventional	2021-06-01	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics. Frontiers in cellular and infection microbiology, 2020, Volume: 10 Topics: Acute Kidney Injury; Amantadine; Angiotensin-Converting Enzyme 2; Cathepsin L; Chloroquine; COVID-19	2020
[Anti-inflammatory effects of amantadine and memantine in SARS-CoV-2 infection]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2021, 02-24, Volume: 49, Issue:289 Topics: Amantadine; Anti-Inflammatory Agents; COVID-19; Humans; Memantine; SARS-CoV-2	2021

Article	Year
Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study. Respiratory medicine, 2023, Volume: 212 Topics: Amantadine; COVID-19; Double-Blind Method; Female; Humans; Male; Middle Aged; Patients; SARS-CoV-2;	2023
Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2023, Volume: 29, Issue:10 Topics: Adolescent; Adult; Amantadine; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Humans; Pande	2023

Article	Year
The efficacy of amantadine hydrochloride in the treatment of COVID-19 - a single-center observation study. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2021, 12-16, Volume: 49, Issue:294 Topics: Amantadine; COVID-19; COVID-19 Testing; Humans; Male; Middle Aged; Prospective Studies; Retrospectiv	2021
The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design. Contemporary clinical trials, 2022, Volume: 116 Topics: Amantadine; COVID-19; COVID-19 Drug Treatment; Humans; Post-Acute COVID-19 Syndrome; Respiratory Ins	2022
COVID-19-Associated Benzodiazepine-Resistant Catatonia Responds to Amantadine. The primary care companion for CNS disorders, 2022, 11-17, Volume: 24, Issue:6 Topics: Amantadine; Benzodiazepines; Catatonia; COVID-19; Electroconvulsive Therapy; Humans	2022
COVID-19-Associated Benzodiazepine-Resistant Catatonia Responds to Amantadine. The primary care companion for CNS disorders, 2022, 11-17, Volume: 24, Issue:6 Topics: Amantadine; Benzodiazepines; Catatonia; COVID-19; Electroconvulsive Therapy; Humans	2022
COVID-19-Associated Benzodiazepine-Resistant Catatonia Responds to Amantadine. The primary care companion for CNS disorders, 2022, 11-17, Volume: 24, Issue:6 Topics: Amantadine; Benzodiazepines; Catatonia; COVID-19; Electroconvulsive Therapy; Humans	2022
COVID-19-Associated Benzodiazepine-Resistant Catatonia Responds to Amantadine. The primary care companion for CNS disorders, 2022, 11-17, Volume: 24, Issue:6 Topics: Amantadine; Benzodiazepines; Catatonia; COVID-19; Electroconvulsive Therapy; Humans	2022
COVID-19-Associated Benzodiazepine-Resistant Catatonia Responds to Amantadine. The primary care companion for CNS disorders, 2022, 11-17, Volume: 24, Issue:6 Topics: Amantadine; Benzodiazepines; Catatonia; COVID-19; Electroconvulsive Therapy; Humans	2022
COVID-19-Associated Benzodiazepine-Resistant Catatonia Responds to Amantadine. The primary care companion for CNS disorders, 2022, 11-17, Volume: 24, Issue:6 Topics: Amantadine; Benzodiazepines; Catatonia; COVID-19; Electroconvulsive Therapy; Humans	2022
COVID-19-Associated Benzodiazepine-Resistant Catatonia Responds to Amantadine. The primary care companion for CNS disorders, 2022, 11-17, Volume: 24, Issue:6 Topics: Amantadine; Benzodiazepines; Catatonia; COVID-19; Electroconvulsive Therapy; Humans	2022
COVID-19-Associated Benzodiazepine-Resistant Catatonia Responds to Amantadine. The primary care companion for CNS disorders, 2022, 11-17, Volume: 24, Issue:6 Topics: Amantadine; Benzodiazepines; Catatonia; COVID-19; Electroconvulsive Therapy; Humans	2022
COVID-19-Associated Benzodiazepine-Resistant Catatonia Responds to Amantadine. The primary care companion for CNS disorders, 2022, 11-17, Volume: 24, Issue:6 Topics: Amantadine; Benzodiazepines; Catatonia; COVID-19; Electroconvulsive Therapy; Humans	2022
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report. International journal of environmental research and public health, 2022, 11-27, Volume: 19, Issue:23 Topics: Amantadine; COVID-19; Humans; Psychotic Disorders; SARS-CoV-2	2022
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report. International journal of environmental research and public health, 2022, 11-27, Volume: 19, Issue:23 Topics: Amantadine; COVID-19; Humans; Psychotic Disorders; SARS-CoV-2	2022
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report. International journal of environmental research and public health, 2022, 11-27, Volume: 19, Issue:23 Topics: Amantadine; COVID-19; Humans; Psychotic Disorders; SARS-CoV-2	2022
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report. International journal of environmental research and public health, 2022, 11-27, Volume: 19, Issue:23 Topics: Amantadine; COVID-19; Humans; Psychotic Disorders; SARS-CoV-2	2022
Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study. Parkinsonism & related disorders, 2023, Volume: 106 Topics: Aged; Amantadine; Cohort Studies; COVID-19; Humans; Male; Middle Aged; Morbidity; Parkinson Disease;	2023
Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study. Parkinsonism & related disorders, 2023, Volume: 106 Topics: Aged; Amantadine; Cohort Studies; COVID-19; Humans; Male; Middle Aged; Morbidity; Parkinson Disease;	2023
Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study. Parkinsonism & related disorders, 2023, Volume: 106 Topics: Aged; Amantadine; Cohort Studies; COVID-19; Humans; Male; Middle Aged; Morbidity; Parkinson Disease;	2023
Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study. Parkinsonism & related disorders, 2023, Volume: 106 Topics: Aged; Amantadine; Cohort Studies; COVID-19; Humans; Male; Middle Aged; Morbidity; Parkinson Disease;	2023
Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome? Expert review of clinical pharmacology, 2023, Volume: 16, Issue:2 Topics: Alzheimer Disease; Amantadine; COVID-19; Humans; Memantine; Parkinson Disease; Post-Acute COVID-19 S	2023
Ethical challenges of clinical trials with a repurposed drug in outbreaks. Medicine, health care, and philosophy, 2023, Volume: 26, Issue:2 Topics: Amantadine; COVID-19; Drug Repositioning; Humans; Pandemics	2023
Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment. International journal of antimicrobial agents, 2020, Volume: 55, Issue:6 Topics: Amantadine; Antiviral Agents; Betacoronavirus; Cathepsin B; Cathepsin L; Cell Line; Coronavirus Infe	2020
Amantadine as a drug to mitigate the effects of COVID-19. Medical hypotheses, 2020, Volume: 140 Topics: Amantadine; Betacoronavirus; Coronavirus Envelope Proteins; Coronavirus Infections; COVID-19; COVID-	2020
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Multiple sclerosis and related disorders, 2020, Volume: 42 Topics: Adamantane; Adult; Aged; Aged, 80 and over; Amantadine; Asymptomatic Infections; Betacoronavirus; Co	2020
The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects. Journal of medical virology, 2020, Volume: 92, Issue:11 Topics: Adamantane; Amantadine; COVID-19; Humans; Lysosomes; Memantine; Respiratory Distress Syndrome; Respi	2020
Does amantadine have a protective effect against COVID-19? Neurologia i neurochirurgia polska, 2020, Volume: 54, Issue:3 Topics: Amantadine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral;	2020
Response to "Does amantadine have a protective effect against COVID-19?" Neurologia i neurochirurgia polska, 2020, Volume: 54, Issue:3 Topics: Amantadine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral;	2020
Amantadine, COVID-19 and Parkinsonism. Archives of medical research, 2020, Volume: 51, Issue:7 Topics: Amantadine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Parkinsonian Disor	2020
Response to: Amantadine, COVID-19 and Parkinsonism. Archives of medical research, 2020, Volume: 51, Issue:7 Topics: Amantadine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Parkinsonian Disor	2020
Amantadine for COVID-19. Journal of clinical pharmacology, 2021, Volume: 61, Issue:3 Topics: Amantadine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Fatigue; Humans; Multiple Sclerosis	2021
Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses, 2021, 03-24, Volume: 13, Issue:4 Topics: Amantadine; Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Huma	2021
[Amantadine in the treatment of Parkinson's disease. New opportunities in the context of COVID-19]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2021, Volume: 121, Issue:4 Topics: Amantadine; Antiparkinson Agents; COVID-19; Humans; Levodopa; Parkinson Disease; SARS-CoV-2	2021

amantadine and 2019 Novel Coronavirus Disease

Research Excerpts

Research

Studies (22)

Authors

Clinical Trials (2)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Bodnar, W	1
Aranda-Abreu, G	1
Słaboń-Willand, M	2
Kotecka, S	2
Farnik, M	2
Bodnar, J	1
Rejdak, K	3
Fiedor, P	1
Bonek, R	1
Goch, A	1
Gala-Błądzińska, A	1
Chełstowski, W	1
Łukasiak, J	1
Kiciak, S	1
Dąbrowski, P	1
Dec, M	1
Król, ZJ	1
Papuć, E	1
Zasybska, A	1
Segiet, A	1
Grieb, P	3
Oh, J	3
Amber-Monta, K	3
Sahota, PC	3
Pradhan, BK	3
Koola, MM	3
Tatar, D	2
Świerzy, K	2
Błachut, M	2
Badura Brzoza, K	2
Przytuła, F	2
Kasprzak, J	2
Dulski, J	2
Koziorowski, D	2
Kwaśniak-Butowska, M	2
Sołtan, W	2
Roszmann, A	2
Śmiłowska, K	2
Schinwelski, M	2
Sławek, J	2
Müller, T	1
Riederer, P	1
Kuhn, W	1
Klas, K	1
Strzebonska, K	1
Waligora, M	1
Barczyk, A	1
Czajkowska-Malinowska, M	1
Barczyk, M	1
Boda, Ł	1
Cofta, S	1
Duława, J	1
Dyrbuś, M	1
Harat, R	1
Huk, M	1
Nahorecki, A	1
Nasiłowski, J	1
Naumnik, W	1
Przybylski, G	1
Skoczyński, S	1
Wita, K	1
Zioło, G	1
Kuna, P	1
Weis, N	1
Bollerup, S	1
Sund, JD	1
Glamann, JB	1
Vinten, C	1
Jensen, LR	1
Sejling, C	1
Kledal, TN	1
Rosenkilde, MM	1
Smieszek, SP	1
Przychodzen, BP	1
Polymeropoulos, MH	1
Abreu, GEA	1
Aguilar, MEH	1
Covarrubias, DH	1
Durán, FR	1
Brenner, SR	1
Cortés Borra, A	1
Tipton, PW	1
Wszolek, ZK	1
Wiwanitkit, V	1
Aranda-Abreu, GE	1
Świątkiewicz, M	1
Prus, K	1
Gomes, CP	1
Fernandes, DE	1
Casimiro, F	1
da Mata, GF	1
Passos, MT	1
Varela, P	1
Mastroianni-Kirsztajn, G	1
Pesquero, JB	1
Płusa, T	1
Fink, K	1
Nitsche, A	1
Neumann, M	1
Grossegesse, M	1
Eisele, KH	1
Danysz, W	1
Katunina, EA	1